vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and PARK AEROSPACE CORP (PKE). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $17.3M, roughly 1.1× PARK AEROSPACE CORP). PARK AEROSPACE CORP runs the higher net margin — 17.0% vs -0.8%, a 17.8% gap on every dollar of revenue. On growth, PARK AEROSPACE CORP posted the faster year-over-year revenue change (20.3% vs -25.7%). PARK AEROSPACE CORP produced more free cash flow last quarter ($4.3M vs $-15.8M). Over the past eight quarters, PARK AEROSPACE CORP's revenue compounded faster (3.0% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Park Electrochemical Corp, now called the Park Aerospace Corp, is a Melville, New York-based materials manufacturer for the telecommunications, Internet infrastructure, high-end computing, and aerospace industries. It produces high-technology digital and radio frequency(RF)/microwave printed circuit material products, composite materials. Its printed circuit materials are used for complex multilayer printed circuit boards and other electronic interconnection systems, such as multilayer back-p...
CTMX vs PKE — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $17.3M |
| Net Profit | $-154.0K | $3.0M |
| Gross Margin | — | 34.1% |
| Operating Margin | -6.9% | 21.0% |
| Net Margin | -0.8% | 17.0% |
| Revenue YoY | -25.7% | 20.3% |
| Net Profit YoY | 97.6% | 87.1% |
| EPS (diluted) | — | $0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $17.3M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | $18.7M | $15.4M | ||
| Q1 25 | $50.9M | $16.9M | ||
| Q4 24 | $38.1M | $14.4M | ||
| Q3 24 | $33.4M | $16.7M | ||
| Q2 24 | $25.1M | $14.0M | ||
| Q1 24 | $41.5M | $16.3M |
| Q4 25 | — | $3.0M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $-154.0K | $2.1M | ||
| Q1 25 | $23.5M | $1.2M | ||
| Q4 24 | $18.9M | $1.6M | ||
| Q3 24 | $5.7M | $2.1M | ||
| Q2 24 | $-6.5M | $993.0K | ||
| Q1 24 | $13.8M | $2.7M |
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 31.2% | ||
| Q2 25 | — | 30.6% | ||
| Q1 25 | — | 29.3% | ||
| Q4 24 | — | 26.6% | ||
| Q3 24 | — | 28.5% | ||
| Q2 24 | — | 29.3% | ||
| Q1 24 | — | 27.3% |
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.4% | ||
| Q2 25 | -6.9% | 15.7% | ||
| Q1 25 | 44.4% | 16.8% | ||
| Q4 24 | 46.4% | 12.8% | ||
| Q3 24 | 12.3% | 15.7% | ||
| Q2 24 | -33.7% | 14.9% | ||
| Q1 24 | 28.1% | 15.7% |
| Q4 25 | — | 17.0% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | -0.8% | 13.5% | ||
| Q1 25 | 46.2% | 7.4% | ||
| Q4 24 | 49.6% | 10.9% | ||
| Q3 24 | 17.2% | 12.4% | ||
| Q2 24 | -26.0% | 7.1% | ||
| Q1 24 | 33.3% | 16.3% |
| Q4 25 | — | $0.15 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | — | $0.10 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | — | $0.10 | ||
| Q2 24 | — | $0.05 | ||
| Q1 24 | — | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $63.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $106.6M |
| Total Assets | $175.1M | $118.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $63.6M | ||
| Q3 25 | — | $61.6M | ||
| Q2 25 | $49.0M | $65.6M | ||
| Q1 25 | $47.6M | $68.8M | ||
| Q4 24 | $38.1M | $70.0M | ||
| Q3 24 | $40.6M | $72.0M | ||
| Q2 24 | $43.2M | $74.4M | ||
| Q1 24 | $36.2M | $77.2M |
| Q4 25 | — | $106.6M | ||
| Q3 25 | — | $105.8M | ||
| Q2 25 | $119.9M | $105.0M | ||
| Q1 25 | $25.0M | $107.2M | ||
| Q4 24 | $-456.0K | $107.4M | ||
| Q3 24 | $-23.5M | $110.3M | ||
| Q2 24 | $-31.2M | $111.7M | ||
| Q1 24 | $-31.7M | $112.9M |
| Q4 25 | — | $118.1M | ||
| Q3 25 | — | $116.4M | ||
| Q2 25 | $175.1M | $120.7M | ||
| Q1 25 | $98.5M | $122.1M | ||
| Q4 24 | $120.5M | $124.2M | ||
| Q3 24 | $139.0M | $125.1M | ||
| Q2 24 | $159.2M | $129.4M | ||
| Q1 24 | $184.7M | $132.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $5.1M |
| Free Cash FlowOCF − Capex | $-15.8M | $4.3M |
| FCF MarginFCF / Revenue | -84.6% | 24.6% |
| Capex IntensityCapex / Revenue | 0.1% | 4.8% |
| Cash ConversionOCF / Net Profit | — | 1.73× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $3.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.1M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | $-15.8M | $1.6M | ||
| Q1 25 | $-21.0M | $969.0K | ||
| Q4 24 | $-19.9M | $2.7M | ||
| Q3 24 | $-20.7M | $1.4M | ||
| Q2 24 | $-19.5M | $-423.0K | ||
| Q1 24 | $-26.0M | $5.3M |
| Q4 25 | — | $4.3M | ||
| Q3 25 | — | $-2.3M | ||
| Q2 25 | $-15.8M | $1.1M | ||
| Q1 25 | $-21.2M | $338.0K | ||
| Q4 24 | $-20.0M | $2.7M | ||
| Q3 24 | $-20.7M | $1.3M | ||
| Q2 24 | $-19.6M | $-435.0K | ||
| Q1 24 | $-26.2M | $5.1M |
| Q4 25 | — | 24.6% | ||
| Q3 25 | — | -14.0% | ||
| Q2 25 | -84.6% | 7.2% | ||
| Q1 25 | -41.6% | 2.0% | ||
| Q4 24 | -52.5% | 18.6% | ||
| Q3 24 | -62.1% | 7.5% | ||
| Q2 24 | -78.2% | -3.1% | ||
| Q1 24 | -63.1% | 31.4% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | 0.1% | 3.1% | ||
| Q1 25 | 0.2% | 3.7% | ||
| Q4 24 | 0.2% | 0.4% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.4% | 0.1% | ||
| Q1 24 | 0.3% | 1.0% |
| Q4 25 | — | 1.73× | ||
| Q3 25 | — | -0.88× | ||
| Q2 25 | — | 0.76× | ||
| Q1 25 | -0.89× | 0.78× | ||
| Q4 24 | -1.05× | 1.73× | ||
| Q3 24 | -3.61× | 0.70× | ||
| Q2 24 | — | -0.43× | ||
| Q1 24 | -1.89× | 1.98× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
PKE
| North America | $16.8M | 97% |
| Other | $546.0K | 3% |
